QSAR Reimagined: Harnessing AI and Multi-omics for Next-generation Drug Discovery
Abstract
Any successful medicinal chemist should appreciate the usefulness of the Quantitative Structure-Activity Relationship (QSAR) technique to derive an estimate of biological effect based on a given chemical structure. Because of the enhanced computer technology available today, the approaches a drug discovery scientist can take when using QSAR modeling have multiplied exponentially. A structured literature search was conducted using PubMed, Scopus, and Google Scholar with keywords including quantitative structure–activity relationship, deep learning, graph neural networks, molecular dynamics, molecular descriptors, multi-omics, and explainable artificial intelligence. Relevant peer-reviewed studies were screened based on their relevance to this minireview. Recent advances in deep learning- and graph neural network-based QSAR modeling, including molecular descriptors, large datasets, multi-omics, and explainable artificial intelligence, were summarized. Enhanced QSAR models outperform other models in predicting drug efficacy, toxicity, and ADMET. QSAR models integrated with generative capabilities assist in the development of drugs. In federated learning, models are trained without shared direct access to data. When applied to clinical data, the models predict with clinical relevance. There is evidence of optimized clinical relevance between preclinical and patient outcomes. Enhanced QSAR possesses unique capabilities in Novel Drug Design, alongside federated and generative learning frameworks. With predictive modeling to its fullest, it possesses great capabilities. Enhanced QSAR models need to focus on the challenges of data quality, model validation, and model interpretability. Informed predictive modeling will extend QSAR into greater therapeutics and personalized medicine. Next-generation QSAR models integrating deep learning, graph neural networks, multi-omics data, and explainable AI provide improved prediction of drug efficacy, toxicity, and ADMET properties. Despite challenges related to data quality, validation, and interpretability, these advanced approaches offer promising opportunities for accelerating drug discovery, precision medicine, and clinically relevant therapeutic development.